Peroxisome proliferator-activated receptor delta and cardiovascular disease |
| |
Authors: | Ewa Ehrenborg Josefin Skogsberg |
| |
Affiliation: | 1. Atherosclerosis Research Unit, Department of Medicine, Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, SE-171 76 Stockholm, Sweden;2. Cardiovascular Genomics Group, Vascular Biology Unit, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-171 77 Stockholm, Sweden |
| |
Abstract: | Recent reports have shown that peroxisome proliferator-activated receptor delta (PPARD) plays an important role in different vascular processes suggesting that PPARD is a significant modulator of cardiovascular disease. This review will focus on PPARD in relation to cardiovascular risk factors based on cell, animal and human data. Mouse studies suggest that Ppard is an important metabolic modulator that may have implications for cardiovascular disease (CVD). Specific human PPARD gene variants show no clear association with CVD but interactions between variants and lifestyle factors might influence disease risk. During recent years, development of specific and potent PPARD agonists has also made it possible to study the effects of PPARD activation in humans. PPARD agonists seem to exert beneficial effects on dyslipidemia and insulin-resistant syndromes but safety issues have been raised due to the role that PPARD plays in cell proliferation. Thus, large long term outcome as well as detailed safety and tolerability studies are needed to evaluate whether PPARD agonists could be used to treat CVD in humans. |
| |
Keywords: | Peroxisome proliferator-activated receptor delta Cardiovascular disease Risk factors Mouse models Agonist Single nucleotide polymorphism |
本文献已被 ScienceDirect 等数据库收录! |
|